公开(公告)号：US20210388015A1

公开(公告)日：2021-12-16

申请号：US17288575

申请日：2019-10-24

申请人： Janssen Pharmaceutica NV

发明人： Guozhang Xu

IPC分类号： C07H7/04 ,  C07H7/06

摘要： The present invention is directed to glucopyranose derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.

公开(公告)号：US11198703B2

公开(公告)日：2021-12-14

申请号：US16612028

申请日：2018-05-09

申请人： PIRAMAL ENTERPRISES LIMITED

发明人： Milind Gharpure ,  Sanjay Kumar Sharma ,  Sandesh Vishwasrao ,  Prasad Vichare ,  Dipak Varal

IPC分类号： C07H7/04 ,  C07H1/00 ,  C07H1/06 ,  C07H7/06

摘要： The present invention relates to an industrially feasible and economically viable process for preparation of Bexagliflozin of formula V in significantly high yield and purity.

公开(公告)号：US10981942B2

公开(公告)日：2021-04-20

申请号：US16694642

申请日：2019-11-25

申请人： THERACOS SUB, LLC

发明人： Mengzhuang Cai ,  Qian Liu ,  Ge Xu ,  Binhua Lv ,  Brian Seed ,  Jacques Roberge

IPC分类号： A61K31/351 ,  C07D309/10 ,  A61P3/10 ,  C07H1/06 ,  C07H7/04

摘要： Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

公开(公告)号：US10913761B2

公开(公告)日：2021-02-09

申请号：US16837191

申请日：2020-04-01

申请人： Vertex Pharmaceuticals Incorporated

发明人： Yeeman K. Ramtohul ,  Sanjoy Kumar Das ,  Caroline Cadilhac ,  Thumkunta Jagadeeswar Reddy ,  Louis Vaillancourt ,  Michel Gallant ,  Bingcan Liu ,  Evelyne Dietrich ,  Frederic Vallee ,  Julien Martel ,  Carl Poisson

IPC分类号： C07D495/04 ,  C07H7/02 ,  C07D407/14 ,  C07D405/14 ,  C07D309/10 ,  C07H15/26 ,  C07D409/14 ,  C07H19/056 ,  C07D417/14 ,  C07H7/04 ,  C07H7/06 ,  C07H19/02 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/7036 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K31/706 ,  A61K31/7064 ,  C07D413/14

摘要： The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

公开(公告)号：US10752604B2

公开(公告)日：2020-08-25

申请号：US16067707

申请日：2017-01-03

申请人： Je II Pharmaceutical Co., Ltd.

发明人： Joon Woo Nam ,  Jong Yup Kim ,  Kyung Hoon Kim ,  Jung Mee Lee ,  Ji Yoon Kim ,  Ji Seon Park ,  Joseph Kim ,  Yoon Sun Park ,  Jeong Min Kim

IPC分类号： C07H15/203 ,  C07H7/04 ,  C07D309/10 ,  A61K31/7034 ,  A61P3/10

摘要： The present disclosure relates to C-glycoside derivatives having a fused phenyl ring or pharmaceutical acceptable salts thereof, a method for preparing the same, a pharmaceutical composition comprising the same, a use thereof and a method for dual inhibition of SGLT1 and SGLT2 using the same. A novel compound of the present disclosure has a dual inhibitory activity against SGLT1 and SGLT2, thus being valuably used as a diabetes therapeutic agent.

公开(公告)号：US20200222423A1

公开(公告)日：2020-07-16

申请号：US16658542

申请日：2019-10-21

申请人： Boehringer Ingelheim International GmbH

发明人： Marion WIENRICH ,  Eric Williams MAYOUX

IPC分类号： A61K31/5513 ,  A61K31/4515 ,  A61K31/551 ,  A61K31/7034 ,  A61K31/7048 ,  A61K45/06 ,  C07H7/04 ,  A61K31/351 ,  A61K31/381

摘要： The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an SGLT2 inhibitor.

公开(公告)号：US20200048491A1

公开(公告)日：2020-02-13

申请号：US16344416

申请日：2017-05-30

申请人： Oji Holdings Corporation

发明人： Kazuyo MORITA ,  Kimiko HATTORI

IPC分类号： C09D133/14 ,  C07H13/04 ,  C08F220/68 ,  C07H7/04 ,  C08F212/14 ,  B05D1/36 ,  B05D7/24

摘要： It is an object of the present invention to provide a pattern forming method capable of easily forming a phase-separated structure with high accuracy, even in the case of widening the applicable range of a pattern size. The present invention relates to a pattern forming method comprising: applying an under coating agent onto a substrate, and applying a self-assembly composition for pattern formation to the surface of the substrate, onto which the under coating agent has been applied, and then forming a self-assembly film according to self-assembly phase separation, wherein the self-assembly composition for pattern formation comprises a block copolymer comprising a polymerization unit (a) having at least one selected from a structure represented by a formula (103) and a structure represented by a formula (104), and a polymerization unit (b) having a structure represented by a formula (105).

公开(公告)号：US10556877B2

公开(公告)日：2020-02-11

申请号：US15571112

申请日：2016-05-04

申请人： Glenmark Life Sciences Limited

发明人： Shekhar Bhaskar Bhirud ,  Kumar Hari Bhushan ,  Raghu Ram Suraparaju ,  Nandkumar Gaikwad ,  Sharad Gore ,  Rajendra Jagdhane ,  Mandar Kulkarni

IPC分类号： C07D309/10 ,  A61K31/70 ,  B01D9/00 ,  C07B51/00 ,  C07B63/04 ,  C07C31/20 ,  C07H7/04

摘要： The present invention relates to a process for the preparation of amorphous dapagliflozin. The present invention relates to 2,3-butanediol solvate of dapagliflozin and process for its preparation.

公开(公告)号：US10538547B2

公开(公告)日：2020-01-21

申请号：US16231960

申请日：2018-12-25

申请人： CHANGZHOU DEZE MEDICAL SCIENCE CO., LTD

发明人： Houlei Teng ,  Wei Wu

IPC分类号： C07H1/00 ,  C07H1/06 ,  C07H7/04 ,  C07H7/06 ,  C07D455/03

摘要： The present invention provides a mangiferin-6-O-calcium salt and a preparation process thereof. In addition, use of the mangiferin-6-O-calcium salt as defined in claim 1 as an intermediate in the preparation of a mangiferin-6-O-berberine salt is also provided.

公开(公告)号：US10533032B2

公开(公告)日：2020-01-14

申请号：US15804074

申请日：2017-11-06

申请人： THERACOS SUB, LLC

发明人： Mengzhuang Cai ,  Qian Liu ,  Ge Xu ,  Binhua Lv ,  Brian Seed ,  Jacques Roberge

IPC分类号： A61P3/10 ,  A61K31/351 ,  C07D309/10 ,  C07H1/06 ,  C07H7/04

摘要： Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.